<DOC>
	<DOCNO>NCT00644033</DOCNO>
	<brief_summary>The primary objective study determine whether frovatriptan effective prevention menstrually associate migraine ( MAM ) headache compare placebo . Secondary objective include determine effectiveness frovatriptan reduce incidence , severity duration MAM headache associate symptom , evaluate safety tolerability two frovatriptan dose regimen compare effectiveness regimen prevention MAM headache . In cross-over study , patient treat 3 perimenstrual period ( PMPs ) placebo , frovatriptan 2.5 mg daily ( QD ) 2.5 mg twice daily ( BID ) 6 day , start 2 day anticipate onset MAM headache . A statistically significant reduction incidence MAM headache ( p &lt; 0.0001 ) observe dose regimen frovatriptan compare placebo . Additionally , frovatriptan BID regimen superior frovatriptan QD regimen prevention MAM headache ( p &lt; 0.001 ) . Significant reduction MAM headache severity duration , incidence associate symptom characteristic , use rescue medication observe PMP treat frovatriptan , compare placebo . Both dose regimen frovatriptan equally well tolerated cardiovascular safety tolerability concern arose repeat administration frovatriptan 6 day period .</brief_summary>
	<brief_title>A Randomized Trial Frovatriptan Intermittent Prevention Menstrual Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Females age 18 year 12 month document history menstrual migraine headache , accord International Headache Society classification An average frequency MAM attack lease 3 4 menstrual cycle Regular predictable menstrual period Able accurately predict onset MAM headache occur Day 2 Day +4 menses Able willing sign inform consent comply study procedure , include completion diary card More three migraine attack per month MAM attack Coronary artery disease include coronary vasospasm Significant cerebrovascular disease include basilar hemiplegic migraine Uncontrolled hypertension Severe hepatic renal insufficiency More 15 headache day per month Any condition serious illness would interfere optimal participation study History clinically relevant allergy , include frovatriptan triptans Pregnant breast feed intend become pregnant breastfeed study period Participated frovatriptan menstrual migraine prevention study Use another investigation drug within 30 day 5 halflives ( whichever longer ) screen visit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>